Focus: Nihon Kohden is a public medical electronics manufacturer headquartered in New York, specializing in cardiovascular, respiratory, and neurology monitoring devices. The company operates as an established player in non-invasive physiological monitoring technology with global reach.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +4 jobs in 30d
5 added, 1 removed. Backfill posture.
Best fit for medical device, diagnostics, or clinical monitoring professionals; poor immediate opportunity for traditional pharmaceutical development roles.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core product with multiple trial validations across clinical settings; foundational to company's non-invasive monitoring portfolio.
Help build intelligence for Nihon Kohden
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Nihon Kohden's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Established hemodynamic monitoring device supporting critical care cardiovascular management.
AI-enabled clinical decision support represents modernization of traditional monitoring toward predictive/preventive care.
Nihon Kohden launches Life Scope E7 patient monitoring platform in India - Indian Pharma Post
Nihon Kohden launches Life Scope E7 patient monitoring platform in India Indian Pharma Post
OpenAI-Novo Nordisk Partnership Targets AI Drug Discovery - Digital Health News
OpenAI-Novo Nordisk Partnership Targets AI Drug Discovery Digital Health News
Nihon Kohden and Hemas Surgicals introduce Next-Generation Cereb Air EEG Technology - dailynews.lk
Nihon Kohden and Hemas Surgicals introduce Next-Generation Cereb Air EEG Technology dailynews.lk
Nihon Kohden Secures Service Contract with Novation Healthcare - respiratory-therapy.com
Nihon Kohden Secures Service Contract with Novation Healthcare respiratory-therapy.com
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Prediction of Atrial Fibrillation Using Artificial Intelligence-Enhanced Electrocardiography - Does Left Atrial Size Matter?
Artificial Intelligence-Enhanced Electrocardiography for Predicting Paroxysmal Atrial Fibrillation From Sinus Rhythm: Impact of Data Integration Across Institutions and Devices.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo